GO:1901991 negative regulation of mitotic cell cycle phase transition: Checkpoint Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901991 describes any process that stops, prevents or reduces the frequency, rate or extent of mitotic cell cycle phase transition, acting as a brake on cell division.
• The term is a biological_process child of negative regulation of cell cycle phase transition and is central to checkpoint control at G1/S, G2/M and the metaphase-to-anaphase transition.
• Key molecular brakes include WEE1 kinase, which phosphorylates CDK1 to delay mitotic entry, and ubiquitin-ligase oscillators such as APC/C that degrade mitotic targets.
• Loss of negative regulation causes unscheduled proliferation and genomic instability, linking GO:1901991 to cancer, developmental disorders and chemotherapy response.
• Researchers study this term with transcriptomics, phospho-proteomics, live-cell imaging and CRISPR knockout or point-mutation models of checkpoint genes.
• EDITGENE provides knockout, point-mutation, knock-in, overexpression cell models and CRISPR library screening to dissect negative regulation of mitotic cell cycle phase transition.
Description
GO:1901991, negative regulation of mitotic cell cycle phase transition, is a Gene Ontology biological_process term that captures every mechanism capable of stopping, preventing or reducing the frequency, rate or extent of transitions between mitotic cell cycle phases. In practical terms, it is the checkpoint brake of the cell division engine: without it, cells would enter S phase or mitosis prematurely or exit mitosis with damaged chromosomes. The term is therefore essential for understanding how normal proliferation is restrained and how that restraint fails in disease. Mechanistically, negative regulation of mitotic cell cycle phase transition is enforced by reversible phosphorylation and by timed proteolysis. WEE1 kinase phosphorylates CDK1 at inhibitory residues to keep the G2/M transition off until DNA replication and repair are complete. Ubiquitin-ligase oscillators, including the anaphase-promoting complex/cyclosome, remove mitotic cyclins and other targets, creating an irreversible directionality to phase transitions. Mathematical models show that two mutually inhibitory oscillators can generate the robust, switch-like behavior characteristic of these negative regulatory events. For researchers, GO:1901991 provides a controlled vocabulary to annotate genes, interpret transcriptomic and proteomic datasets, and design perturbation experiments. Because the term is defined by outcome rather than by a single pathway, it encompasses kinase cascades, phosphatase reactions, ubiquitin-dependent degradation and transcriptional repression that collectively delay or block mitotic phase transitions. This makes it a powerful framework for comparing cell cycle control across species and for identifying therapeutic vulnerabilities in proliferative diseases.
negative regulation of mitotic cell cycle phase transition At A Glance
| GO ID | GO:1901991 |
|---|---|
| GO term | negative regulation of mitotic cell cycle phase transition |
| Ontology | biological_process |
| Synonym | down regulation of mitotic cell cycle phase transition; down-regulation of mitotic cell cycle phase transition; downregulation of mitotic cell cycle phase transition; inhibition of mitotic cell cycle phase transition |
| Major function | Stops, prevents or reduces the frequency, rate or extent of mitotic cell cycle phase transition, acting as a checkpoint brake on cell division |
| Parent term | negative regulation of cell cycle phase transition |
| Regulated process | mitotic cell cycle phase transition |
| Example effectors | WEE1 kinase, CDK1 inhibitory phosphorylation, APC/C ubiquitin ligase, cyclin degradation |
| Disease relevance | Cancer, genomic instability and proliferative disorders when negative regulation is lost |
What Is GO:1901991?
In our own words, GO:1901991 refers to any biological process that stops, prevents or reduces the frequency, rate or extent of mitotic cell cycle phase transition. It is a negative regulatory biological_process that acts on the transitions between mitotic cell cycle phases, such as G1/S, G2/M and metaphase-to-anaphase, rather than on a single molecular event.
Why Is negative regulation of mitotic cell cycle phase transition Important in Cell Biology?
GO:1901991 matters because it defines the molecular brakes that prevent premature or inappropriate mitotic cell cycle phase transitions. When these brakes fail, cells can replicate damaged DNA, mis-segregate chromosomes or proliferate without restraint, which are hallmarks of cancer and other proliferative diseases. Conversely, excessive negative regulation can cause cell cycle arrest, senescence or developmental defects, making the term relevant to both oncogenesis and normal development.
• Provides a standardized annotation for genes that delay or block G1/S, G2/M or metaphase-to-anaphase transitions.
• Explains how WEE1-mediated inhibitory phosphorylation of CDK1 prevents premature mitotic entry.
• Links ubiquitin-dependent proteolysis of mitotic targets to irreversible phase transition control.
• Supports mathematical modeling of cell cycle oscillators and checkpoint robustness.
• Helps interpret transcriptomic changes, such as those induced by HDAC inhibitors in melanoma cells.
• Connects cell cycle control to plant and animal developmental diversity.
• Guides CRISPR perturbation studies of checkpoint genes in cancer and stem cell models.
• Informs therapeutic strategies targeting WEE1, APC/C and CDK regulatory networks.
• Enables cross-species comparison of cell cycle regulation from Drosophila to human.
• Underpins biomarker discovery for proliferation status and drug response.
What Happens During negative regulation of mitotic cell cycle phase transition?
Inhibitory phosphorylation of CDK1 by WEE1
In simple terms: A kinase called WEE1 puts a chemical tag on CDK1 that keeps the cell from starting mitosis too early.
WEE1 kinase phosphorylates CDK1 at inhibitory residues, preventing the G2/M transition until DNA replication and damage repair are complete. This phosphorylation is reversed by CDC25 phosphatases, creating a switch-like control point. Cell cycle regulation of human WEE1 itself is tightly controlled, ensuring that the inhibitory signal is present at the right time. This mechanism is a canonical example of negative regulation of mitotic cell cycle phase transition.
Ubiquitin-dependent proteolysis of mitotic targets
In simple terms: A cellular recycling machine tags mitotic proteins for destruction so the cell can move forward or stop at the right moment.
Cell cycle-regulated proteolysis of mitotic target proteins, including cyclins and other regulators, is mediated by ubiquitin-ligase complexes such as the anaphase-promoting complex/cyclosome. Interwoven ubiquitination oscillators control cell cycle transitions by degrading activators and thereby reducing the frequency or extent of phase transitions. This proteolytic layer provides directionality and irreversibility to negative regulation of mitotic cell cycle phase transition.
Oscillator dynamics and checkpoint robustness
In simple terms: Two opposing molecular clocks push and pull each other to make cell division decisions reliable.
Mathematical models describe cell cycle regulation by two mutually inhibitory oscillators, which generate robust switches at phase transitions. These oscillators integrate positive and negative signals, so that negative regulation of mitotic cell cycle phase transition is not a simple on/off event but a dynamic system property. This framework helps explain how cells maintain checkpoint fidelity despite noise.
Transcriptional and epigenetic control of negative regulators
In simple terms: Cells can dial down or up the genes that put the brakes on division.
Whole-transcriptomic profiling of SK-MEL-3 melanoma cells treated with the histone deacetylase inhibitor trichostatin A shows widespread changes in cell cycle gene expression, including regulators of phase transitions. Such epigenetic modulation can alter the abundance of negative regulators and thereby influence GO:1901991 activity. This links chromatin state to the strength of the mitotic cell cycle brake.
Developmental and species-specific tuning
In simple terms: Different organisms and tissues adjust the brakes to suit their own growth needs.
The plant cell cycle has been reviewed with emphasis on conserved and divergent control mechanisms, showing that negative regulation of phase transitions is tuned across kingdoms. In Drosophila, cell cycle diversity involves differential regulation of Cyclin E activity in the bristle cell lineage, illustrating tissue-specific modulation of phase transition control. These examples show that GO:1901991 encompasses evolutionarily diverse strategies for restraining mitotic transitions.
Key Genes Involved in GO:1901991 negative regulation of mitotic cell cycle phase transition
The following genes and proteins are experimentally implicated in negative regulation of mitotic cell cycle phase transition, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| WEE1 | Phosphorylates CDK1 to inhibit G2/M transition | Core negative regulator; target for checkpoint studies and inhibitor development |
| CDK1 | Catalytic subunit of M-phase promoting factor; inhibited by WEE1 phosphorylation | Central node whose inhibitory phosphorylation defines the brake |
| CCNB1 | Mitotic cyclin that activates CDK1; degraded by APC/C | Its destruction contributes to mitotic exit and phase transition control |
| APC/C subunits | Ubiquitin ligase that targets mitotic proteins for degradation | Key proteolytic oscillator enforcing negative regulation |
| CDC25 phosphatases | Remove inhibitory phosphorylation from CDK1 | Opposing regulators that set the threshold for phase transition |
| CCNE1 | G1/S cyclin with differential regulation in Drosophila | Model for tissue-specific phase transition tuning |
| HDACs | Chromatin modifiers affecting cell cycle gene expression | Epigenetic control of negative regulators; studied with trichostatin A |
| SKP1 | Component of SCF ubiquitin ligase complexes | Contributes to ubiquitin-dependent control of cell cycle transitions |
| CUL1 | Scaffold of SCF ubiquitin ligase | Participates in proteolytic regulation of phase transitions |
| FZR1 | Activator of APC/C | Required for timely mitotic exit and negative regulation |
| PLK1 | Mitotic kinase that influences checkpoint recovery | Modulates the balance of positive and negative regulation |
| AURKA | Mitotic kinase involved in spindle assembly checkpoint | Indirectly affects phase transition fidelity |
| MAD2L1 | Spindle assembly checkpoint component | Delays anaphase onset when chromosomes are unattached |
| BUB1B | Spindle checkpoint kinase | Prevents premature metaphase-to-anaphase transition |
| CDKN1A | CDK inhibitor at G1/S | Negative regulator of G1/S transition |
| CDKN1B | CDK inhibitor at G1/S | Negative regulator of G1/S transition |
| TP53 | Transcriptional activator of CDK inhibitors | Indirect negative regulator of phase transitions |
How Is negative regulation of mitotic cell cycle phase transition Regulated?
Negative regulation of mitotic cell cycle phase transition is itself regulated at multiple levels. WEE1 abundance and activity are cell cycle-regulated, ensuring inhibitory phosphorylation of CDK1 occurs at the appropriate time. Ubiquitin-ligase oscillators, including APC/C and SCF complexes, are controlled by phosphorylation and by their own degradation, creating interwoven feedback loops. Mathematical models show that two mutually inhibitory oscillators can generate robust, switch-like transitions, meaning the negative regulation is an emergent property of the network rather than a single linear pathway. Epigenetic modifiers such as histone deacetylases can also shift the expression of cell cycle regulators, as seen in melanoma cells treated with trichostatin A. In plants and Drosophila, developmental signals tune the strength of negative regulation to produce tissue-specific cell cycle patterns.
negative regulation of mitotic cell cycle phase transition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| WEE1 | Cancer; checkpoint abrogation and mitotic catastrophe | WEE1 knockout or point-mutation cancer cell lines |
| CCNE1 | Developmental patterning; cell cycle diversity | Drosophila bristle lineage with tagged CCNE1 knock-in |
| HDACs | Melanoma; epigenetic regulation of cell cycle genes | SK-MEL-3 cells treated with trichostatin A |
| APC/C subunits | Cancer; genomic instability from failed proteolysis | Knockout of FZR1 or APC subunits in human cell lines |
| CDK1 | Proliferative disorders; mitotic entry control | CDK1 point-mutation (inhibitory phosphorylation site) knock-in |
Cancer and genomic instability
Loss of negative regulation of mitotic cell cycle phase transition allows cells to enter mitosis with damaged DNA or to exit mitosis prematurely, promoting genomic instability and tumorigenesis. WEE1 is overexpressed in some cancers and is a therapeutic target because its inhibition forces cells with defective checkpoints into mitotic catastrophe. Transcriptomic profiling of melanoma cells treated with trichostatin A reveals widespread changes in cell cycle regulators, highlighting how epigenetic drugs can perturb these brakes.
Developmental disorders and tissue patterning
Proper negative regulation of phase transitions is required for normal development. In Drosophila, differential regulation of Cyclin E activity in the bristle cell lineage controls cell cycle diversity, and its disruption alters cell fate and tissue patterning. In plants, conserved and divergent cell cycle controls shape growth and development, indicating that GO:1901991 is relevant to developmental biology beyond animals.
Therapeutic targeting of checkpoint kinases
Because WEE1 and other negative regulators enforce checkpoints, inhibitors of these proteins are being explored to sensitize cancer cells to DNA-damaging agents. The concept of interwoven ubiquitination oscillators also suggests that targeting APC/C or SCF complexes could disrupt phase transition control in proliferative diseases. Mathematical models of mutually inhibitory oscillators may guide the design of combination therapies that exploit these vulnerabilities.
From negative regulation of mitotic cell cycle phase transition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of WEE1 accelerate mitotic entry? | WEE1 knockout cell line |
| Does inhibitory phosphorylation of CDK1 control G2/M timing? | CDK1 point-mutation knock-in at inhibitory residues |
| How does APC/C substrate degradation affect phase transitions? | Tagged knock-in of cyclin or APC substrate with degron |
| Can overexpression of a CDK inhibitor block proliferation? | CDKN1A or CDKN1B overexpression cell model |
| How do epigenetic drugs alter cell cycle gene expression? | HDAC inhibitor treatment followed by RNA-seq |
| What is the role of Cyclin E in tissue-specific cell cycles? | Drosophila bristle lineage with CCNE1 knockout or knock-in |
How to Study the negative regulation of mitotic cell cycle phase transition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance of cell cycle regulators | Identify changes in negative regulators after drug treatment |
| Phospho-proteomics | Phosphorylation state of CDK1 and checkpoint kinases | Quantify inhibitory phosphorylation by WEE1 |
| Live-cell imaging | Timing of G1/S, G2/M and anaphase transitions | Detect premature or delayed transitions |
| Ubiquitin chain analysis | Proteolytic targeting of mitotic proteins | Study APC/C and SCF substrate degradation |
| Mathematical modeling | Oscillator dynamics and checkpoint robustness | Predict phase transition behavior |
| CRISPR knockout | Gene function loss | Test requirement for negative regulators |
| CRISPR point mutation | Specific phosphorylation or degron site | Dissect inhibitory phosphorylation of CDK1 |
| Overexpression | Gain of function of negative regulators | Assess cell cycle arrest or delay |
Transcriptomic profiling of cell cycle regulators
RNA-seq and whole-transcriptomic profiling can quantify changes in negative regulators of mitotic cell cycle phase transition after genetic or pharmacological perturbation. For example, SK-MEL-3 melanoma cells treated with trichostatin A show altered expression of cell cycle genes, providing a template for identifying GO:1901991 components.
Phospho-proteomics of CDK1 and checkpoint kinases
Because inhibitory phosphorylation of CDK1 by WEE1 is a central mechanism, phospho-specific antibodies and mass spectrometry can measure the phosphorylation state of CDK1 and related proteins. This approach reveals how negative regulation is toggled during the cell cycle.
Live-cell imaging of phase transitions
Fluorescent reporters for cyclins, CDK activity and chromosome segregation allow real-time measurement of phase transition timing. Such imaging can detect premature or delayed transitions when negative regulators are perturbed.
Mathematical and computational modeling
Ordinary differential equation models of mutually inhibitory oscillators can simulate how negative regulation shapes phase transition dynamics. These models generate predictions that can be tested with CRISPR perturbations.
How CRISPR Can Be Used to Study GO:1901991 negative regulation of mitotic cell cycle phase transition
Knockout
CRISPR knockout of WEE1, APC/C subunits or CDK inhibitors removes negative regulation and can cause premature mitotic entry, genomic instability or cell death. Knockout cell lines are used to test whether a candidate gene is required for the brake on phase transitions.
Point Mutation
Point mutation of the inhibitory phosphorylation sites on CDK1 (such as T14 and Y15) prevents WEE1-mediated negative regulation, allowing direct testing of this phospho-switch in mitotic entry. Similarly, degron mutations in cyclins can stabilize them and alter phase transition timing.
Knock-in
Knock-in of fluorescent or degron tags into endogenous loci enables real-time tracking of negative regulators and their substrates. Tagged cyclins or APC/C substrates allow measurement of proteolysis kinetics during phase transitions.
Overexpression
Overexpression of negative regulators such as CDKN1A, CDKN1B or WEE1 can induce cell cycle arrest or delay, providing gain-of-function evidence for their role in GO:1901991. Overexpression models are useful for testing whether a gene is sufficient to block phase transitions.
How EDITGENE Supports negative regulation of mitotic cell cycle phase transition Research
Researchers studying negative regulation of mitotic cell cycle phase transition-related genes often need to determine whether a candidate gene is causally involved in checkpoint control, whether a specific phosphorylation or degron site is required, and how perturbation alters proliferation. EDITGENE provides the CRISPR tools and cell models to answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mitotic cell cycle phase transition research.
Frequently Asked Questions About negative regulation of mitotic cell cycle phase transition
What is GO:1901991?
GO:1901991 is the Gene Ontology term for negative regulation of mitotic cell cycle phase transition, defined as any process that stops, prevents or reduces the frequency, rate or extent of mitotic cell cycle phase transition.
What genes are involved in negative regulation of mitotic cell cycle phase transition?
Key genes include WEE1, CDK1, CCNB1, APC/C subunits, CDC25 phosphatases, CDKN1A, CDKN1B and TP53, based on published cell cycle studies.
How does WEE1 inhibit the mitotic cell cycle phase transition?
WEE1 phosphorylates CDK1 at inhibitory residues, preventing the G2/M transition until DNA replication and repair are complete.
What is the role of ubiquitination in GO:1901991?
Ubiquitin-ligase oscillators such as APC/C degrade mitotic cyclins and other targets, providing irreversible negative regulation of phase transitions.
Why is negative regulation of mitotic cell cycle phase transition important in cancer?
Loss of these brakes allows unscheduled proliferation and genomic instability, and WEE1 inhibitors are being explored to force cancer cells into mitotic catastrophe.
Which model organisms are used to study GO:1901991?
Human cell lines, Drosophila bristle lineages and plant systems have been used to study conserved and divergent negative regulation of phase transitions.
How can CRISPR help study negative regulation of mitotic cell cycle phase transition?
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of candidate genes and specific phosphorylation or degron sites.
What methods measure negative regulation of mitotic cell cycle phase transition?
RNA-seq, phospho-proteomics, live-cell imaging, ubiquitin chain analysis and mathematical modeling are commonly used.
Is GO:1901991 the same as cell cycle arrest?
No, GO:1901991 is broader: it includes any process that reduces the frequency, rate or extent of mitotic phase transitions, not only complete arrest.
What diseases are linked to defects in GO:1901991?
Cancer, genomic instability and developmental patterning defects have been linked to altered negative regulation of mitotic cell cycle phase transition.
Conclusion
GO:1901991, negative regulation of mitotic cell cycle phase transition, is a fundamental biological_process that captures the brakes on cell division. Its mechanisms include WEE1-mediated inhibitory phosphorylation of CDK1, ubiquitin-dependent proteolysis of mitotic targets, and dynamic oscillator networks that ensure robust checkpoint control. Dysregulation of these brakes contributes to cancer and developmental disorders, making the term a key framework for both basic and translational research. By combining CRISPR knockout, point mutation, knock-in, overexpression and library screening with transcriptomic, proteomic and imaging readouts, researchers can dissect how individual genes contribute to GO:1901991. EDITGENE provides integrated services to accelerate this work and generate publication-ready evidence.
References
- 1. Mazzio EA et al.. 2018. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.. Cancer Genomics Proteomics 15(5):349-364 PMID: 30194076
- 2. McGowan CH et al.. 1995. Cell cycle regulation of human WEE1.. EMBO J 14(10):2166-75 PMID: 7774574
- 3. Bastians H et al.. 1999. Cell cycle-regulated proteolysis of mitotic target proteins.. Mol Biol Cell 10(11):3927-41 PMID: 10564281
- 4. Dragoi CM et al.. 2024. Newton's cradle: Cell cycle regulation by two mutually inhibitory oscillators.. Math Biosci 377:109291 PMID: 39241924
- 5. Francis D. 2007. The plant cell cycle--15 years on.. New Phytol 174(2):261-278 PMID: 17388890
- 6. Nigg EA et al.. 1992. Regulation of p34cdc2 protein kinase activity by phosphorylation and cyclin binding.. Ciba Found Symp 170:72-84; discussion 84-96 PMID: 1483352
- 7. Ang XL et al.. 2004. Interwoven ubiquitination oscillators and control of cell cycle transitions.. Sci STKE 2004(242):pe31 PMID: 15266102
- 8. Audibert A et al.. 2005. Cell cycle diversity involves differential regulation of Cyclin E activity in the Drosophila bristle cell lineage.. Development 132(10):2287-97 PMID: 15829522
